Skip to main content
SpringerLink
Log in

Chemotherapy for Hodgkin’s Disease and Aggressive Non-Hodgkin’s Lymphoma

More is Better, or Is it?

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Anderson JR, Canellos GP, Propert KJ, Cooper R, Nissen N, et al. MOPP vs ABVD vs MOPP alternating with ABVD as treatment for advanced Hodgkin’s Disease. Results at a median follow up of 4 years. Proceedings of the Fourth International Conference on Malignant Lymphoma, Lugano, Abstract no. 16, p. 26, 1990

    Google Scholar 

  • Baer MR, Stein RS, Greer JP, et al. Modified cyclophosphamide, vincristine, methotrexate, leucovorin, cytarabine (COMLA) in intermediate and high grade lymphoma. An effective short course regimen. Cancer Treatment Reports 70: 785–787, 1986

    PubMed  CAS  Google Scholar 

  • Bruce WR, Meeker BE, Valeriote FA. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. Journal of the National Cancer Institute 37: 233–241, 1966

    PubMed  CAS  Google Scholar 

  • Carde P, Mackintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. Journal of Clinical Oncology 1: 146–153, 1983

    PubMed  CAS  Google Scholar 

  • Coiffier B, Shipp MA, Cabanillas F, Crowther D, Armitage JO, et al. Results of the first workshop on prognostic factors in large cell lymphoma. Annals of Oncology 2(Suppl. 2): 213–217, 1991

    Article  PubMed  Google Scholar 

  • Coppin CML. The description of chemotherapy delivery. Options and pitfalls. Seminars in Oncology 14: 34–41, 1987

    PubMed  CAS  Google Scholar 

  • Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y. Dose intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Israel Journal of Medical Sciences 24: 533–538, 1988

    PubMed  CAS  Google Scholar 

  • Frei E, Canellos GP. Dose: a critical factor in cancer chèmotherapy. American Journal of Medicine 69: 585–594, 1980

    Article  PubMed  Google Scholar 

  • Gaynor ER, Ultmann JE, Golómg HM, Sweet DL, et al. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, ‘Oncovin’, methotrexate, leucovorin, cy-tosine arabinoside): a 10 year experience in a single institution. Journal of Clinical Oncology 12: 1596–1604, 1985

    Google Scholar 

  • Gianni AM, Bregni M, Siena S, Brambilla F, Lombardi F, et al. Prospective randomized comparison of MACOP-B vs rhGM-CSF-supported high dose sequential myeloablative chemo-ra-diotherapy in diffuse large cell lymphomas. Proceedings of the American Society of Clinical Oncology, Houston, Abstract no. 951, p. 274, 1991

    Google Scholar 

  • Griswold DP, Laster WR, Snow MY, Schabel FM, Skipper HE. Experimental evaluation of potential anticancer agents. Cancer Research 21(Suppl. 23): 271–303, 1963

    Google Scholar 

  • Gulati SC, Shank B, Black P, et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. Journal of Clinical Oncology 6: 1303–1313, 1988

    PubMed  CAS  Google Scholar 

  • Gurney H, Crowther D, Anderson H, Murphy D, Prendiville J, et al. Five year follow up and dose delivery analysis of cis-platin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Annals of Oncology 1: 427–433, 1990

    PubMed  CAS  Google Scholar 

  • Henry-Amar M, Somers R. Survival outcome after Hodgkin’s disease: a report from the international data base on Hodgkin’s disease. Seminars in Oncology 17: 758–768, 1990

    PubMed  CAS  Google Scholar 

  • Hryniuk W. Randomized trial of escalated (E) vs standard (S) BACOP (bleomycin, adriamycin, cyclophosphamide, ‘On-covin’, prednisone) for intermediate grade lymphoma (IGL). Proceedings of the American Society of Clinical Oncology, Houston. Abstract no. 943, p. 272, 1991

    Google Scholar 

  • Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology 2: 1281–1288, 1984

    PubMed  CAS  Google Scholar 

  • Jagannath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. Journal of Clinical Oncology 7: 179–185, 1989

    PubMed  CAS  Google Scholar 

  • Kessinger A, Nademanee A, Forman SJ, Armitage JO. Autologous bone marrow transplantation for Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplantation 4: 577–587, 1990

    CAS  Google Scholar 

  • Klimo P, Connors JM. An update of the Vancouver experience in the management of advanced Hodgkin’s disease treated with the MOPP/ABV hybrid programme. Seminars in Hematology 25(Suppl. 2): 34–40, 1988

    PubMed  CAS  Google Scholar 

  • Kwak LW, Halpern J, Olshen RA, Homing SJ. Prognostic significance of actual dose intensity in diffuse large cell lymphoma: results of a tree structured survival analysis. Journal of Clinical Oncology 8: 963–977, 1990

    PubMed  CAS  Google Scholar 

  • Lagarde P, Bonichon F, Aghbali H, De Mascarel I, Chauvergne J, et al. Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin’s disease. British Journal of Cancer 59: 645–649, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lee R, Cabanillas F, Bodey GP, et al. A 10 year update of CHOP-bleo in the treatment of diffuse large-cell lymphoma. Journal of Clinical Oncology 4: 1455–1461, 1986

    PubMed  CAS  Google Scholar 

  • Longo DL. The use of chemotherapy in the treatment of Hodgkin’s disease. Seminars in Oncology 17: 716–735, 1990a

    PubMed  CAS  Google Scholar 

  • Longo DL. Chemotherapy for advanced aggressive lymphoma: more is better isn’t it? Journal of Clinical Oncology 8: 952–955, 1990b

    PubMed  CAS  Google Scholar 

  • Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PC, et al. Twenty years of MOPP therapy for Hodgkin’s Disease. Journal of Clinical Oncology 4: 1295–1306, 1986

    PubMed  CAS  Google Scholar 

  • Ng VB, Ragaz J, Spinelli J, Jackson S. Introduction of cumulative dose intensity product for measuring the delivered dose intensity of chemotherapy — analysis of the British Columbia breast cancer randomized study. Proceedings of the American Society of Clinical Oncology 8: 47, 1989

    Google Scholar 

  • Philip T, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, et al. The Parma international randomized prospective study in relapsed non-Hodgkin’s lymphoma. First interim analysis of 128 patients. Proceedings of the Fourth International Conference on Malignant Lymphoma, Lugano, p. 165, 1990

    Google Scholar 

  • Pillai GN, Hagemeister FB, Velasquez WS, Sullivan JA, Johnston DA, et al. Prognostic factors for stage IV Hodgkin’s disease treated with MOPP with or without bleomycin. Cancer 55: 691–697, 1985

    Article  PubMed  CAS  Google Scholar 

  • Radford J, Ganesan T, Crowther D, Lister A, Deakin D, et al. MVPP versus a 7 drug hybrid regimen for Hodgkin’s disease (HD). Initial results of a randomized trial at 2 specialised centres. British Journal of Cancer 63(Suppl. 13): Abstract no. 12, p. 9, 1991

    Google Scholar 

  • Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s Disease. Annals of Internal Medicine 96: 139–144, 1982a

    PubMed  CAS  Google Scholar 

  • Santoro A, Bonadonna G, Bonfante V, Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin’s disease. New England Journal of Medicine 306: 770–775, 1982b

    Article  PubMed  CAS  Google Scholar 

  • Schabel FM, Griswold DP, Corbett TH, et al. Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer 54: 1160–1167, 1984

    Article  PubMed  CAS  Google Scholar 

  • Skipper HE. Biochemical, biological, pharmacologic, toxicologie, kinetic and clinical (subhuman and human) relationships. Cancer 21: 600–610, 1968

    Article  PubMed  CAS  Google Scholar 

  • Tura S, Mazza P, Gharlizoni F. High dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin’s lymphoma. Scandinavian Journal of Haematology 37: 317–323, 1986

    Google Scholar 

  • van Rijswijk RE, Haanen C, Dekker AW, et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin’s disease. Journal of Clinical Oncology 7: 1776–1782, 1989

    PubMed  Google Scholar 

  • Yi PI, Coleman M, Saltz L, Norton L, Topilow AA, et al. Chemotherapy for large cell lymphoma. A status update. Seminars in Oncology 17: 60–73, 1990

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cookridge Hospital, Leeds, LSI6 6QB, England

    D. J. Dodwell

  2. Department of Medical Oncology, Christie Hospital, Manchester, England

    E. S. de Campos & J. A. Radford

Authors
  1. D. J. Dodwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. S. de Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. A. Radford
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dodwell, D.J., de Campos, E.S. & Radford, J.A. Chemotherapy for Hodgkin’s Disease and Aggressive Non-Hodgkin’s Lymphoma. Drugs 44, 1–8 (1992). https://doi.org/10.2165/00003495-199244010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199244010-00001

Search

Navigation